S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war

BioLife Solutions Stock Price, News & Analysis (NASDAQ:BLFS)

$13.25
+0.88 (+7.11%)
(As of 12/1/2023 ET)
Compare
Today's Range
$11.91
$13.30
50-Day Range
$8.99
$14.08
52-Week Range
$8.92
$26.89
Volume
2.24 million shs
Average Volume
554,939 shs
Market Capitalization
$583.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.60

BioLife Solutions MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
85.7% Upside
$24.60 Price Target
Short Interest
Bearish
9.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.90mentions of BioLife Solutions in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$10.37 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.06) to ($0.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

516th out of 957 stocks

Electromedical Equipment Industry

13th out of 23 stocks


BLFS stock logo

About BioLife Solutions Stock (NASDAQ:BLFS)

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Stock Price History

BLFS Stock News Headlines

BioLife Solutions: A Complicated Tale
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
BioLife Solutions Inc BLFS
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
BioLife Solns: Q3 Earnings Insights
Here's what Wall Street expects from Biolife Solutions's earnings report
TD Cowen Reaffirms Their Buy Rating on BioLife Solutions (BLFS)
BioLife Solutions (NASDAQ: BLFS)
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
466
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.60
High Stock Price Target
$28.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+85.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-139,800,000.00
Pretax Margin
-65.96%

Debt

Sales & Book Value

Annual Sales
$161.76 million
Book Value
$7.54 per share

Miscellaneous

Free Float
42,842,000
Market Cap
$583.40 million
Optionable
Not Optionable
Beta
1.61
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report














BLFS Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price target for 2024?

5 Wall Street analysts have issued 12 month price objectives for BioLife Solutions' shares. Their BLFS share price targets range from $22.00 to $28.00. On average, they anticipate the company's stock price to reach $24.60 in the next twelve months. This suggests a possible upside of 85.7% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2023?

BioLife Solutions' stock was trading at $18.20 at the beginning of the year. Since then, BLFS shares have decreased by 27.2% and is now trading at $13.25.
View the best growth stocks for 2023 here
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, November, 9th. The medical equipment provider reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.09. The medical equipment provider had revenue of $33.33 million for the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions had a negative net margin of 66.04% and a negative trailing twelve-month return on equity of 12.70%.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its third quarter 2023 earnings guidance on Thursday, October, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.30 million-$33.30 million, compared to the consensus revenue estimate of $32.72 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.11%), Invesco Ltd. (2.42%), William Blair Investment Management LLC (1.55%), Ameriprise Financial Inc. (1.22%), New York State Common Retirement Fund (0.96%) and Jennison Associates LLC (0.93%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BLFS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -